Alexza Pharmaceuticals Company Profile (NASDAQ:ALXA)

About Alexza Pharmaceuticals (NASDAQ:ALXA)

Alexza Pharmaceuticals logoAlexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company's product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALXA
  • CUSIP: N/A
  • Web: www.alexza.com/
Average Prices:
  • 50 Day Moving Avg: $0.94
  • 200 Day Moving Avg: $0.94
  • 52 Week Range: $0.43 - $1.03
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.80
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -466.94%
  • Return on Assets: -106.54%
 

Frequently Asked Questions for Alexza Pharmaceuticals (NASDAQ:ALXA)

What is Alexza Pharmaceuticals' stock symbol?

Alexza Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXA."

How were Alexza Pharmaceuticals' earnings last quarter?

Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) released its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.72 million for the quarter. View Alexza Pharmaceuticals' Earnings History.

Who are some of Alexza Pharmaceuticals' key competitors?

How do I buy Alexza Pharmaceuticals stock?

Shares of Alexza Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexza Pharmaceuticals' stock price today?

One share of Alexza Pharmaceuticals stock can currently be purchased for approximately $0.94.


MarketBeat Community Rating for Alexza Pharmaceuticals (NASDAQ ALXA)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about Alexza Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alexza Pharmaceuticals (NASDAQ:ALXA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Alexza Pharmaceuticals (NASDAQ:ALXA)
Price Target History for Alexza Pharmaceuticals (NASDAQ:ALXA)
Analysts' Ratings History for Alexza Pharmaceuticals (NASDAQ:ALXA)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Alexza Pharmaceuticals (NASDAQ:ALXA)
Earnings by Quarter for Alexza Pharmaceuticals (NASDAQ:ALXA)
Earnings History by Quarter for Alexza Pharmaceuticals (NASDAQ ALXA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2016Q116($0.16)$0.72 millionViewN/AView Earnings Details
3/28/2016Q415($0.37)($0.15)$1.45 million$0.67 millionViewListenView Earnings Details
11/5/2015Q315($0.34)($0.27)$1.60 million$1.77 millionViewN/AView Earnings Details
8/6/2015Q215($0.66)($0.63)$2.31 million$1.88 millionViewN/AView Earnings Details
5/6/2015Q115($0.51)($0.02)$2.23 million$0.71 millionViewN/AView Earnings Details
3/9/2015Q414($0.80)($0.50)$2.99 million$1.45 billionViewN/AView Earnings Details
8/7/2014Q2($0.67)($0.62)$2.24 million$1.50 millionViewListenView Earnings Details
5/5/2014Q1($0.55)($0.55)$2.36 million$2.17 millionViewListenView Earnings Details
8/8/2013Q2 2013$0.09($0.21)$14.17 million$40.84 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.45)($1.31)$1.00 million$0.73 millionViewListenView Earnings Details
11/7/2012Q312($0.52)$1.86 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alexza Pharmaceuticals (NASDAQ:ALXA)
Current Year EPS Consensus Estimate: $-2.11 EPS
Next Year EPS Consensus Estimate: $-1.17 EPS

Dividends

Dividend History for Alexza Pharmaceuticals (NASDAQ:ALXA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alexza Pharmaceuticals (NASDAQ:ALXA)
Insider Trades by Quarter for Alexza Pharmaceuticals (NASDAQ:ALXA)
Insider Trades by Quarter for Alexza Pharmaceuticals (NASDAQ:ALXA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/21/2016Ferrer Internacional S GrupoMajor ShareholderBuy19,465,714$0.90$17,519,142.60View SEC Filing  
9/6/2013Gordon RingoldDirectorBuy10,000$4.77$47,700.00View SEC Filing  
7/26/2013Thomas Braxton KingCEOBuy40,000$4.48$179,200.00View SEC Filing  
7/26/2013Thomas Braxton KingCEOBuy40,000$4.48$179,200.00View SEC Filing  
1/18/2013Lansdowne Partners Austria GmbMajor ShareholderSell125,000$4.75$593,750.00View SEC Filing  
12/27/2012Lansdowne Partners Austria GmbMajor ShareholderBuy72,189$4.85$350,116.65View SEC Filing  
12/26/2012James V CassellaEVPSell4,558$4.90$22,334.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alexza Pharmaceuticals (NASDAQ:ALXA)
Latest Headlines for Alexza Pharmaceuticals (NASDAQ:ALXA)
Source:
DateHeadline
americanbankingnews.com logoComparing Alexza Pharmaceuticals (ALXA) & Endo International PLC (ENDP)
www.americanbankingnews.com - July 23 at 12:14 PM
americanbankingnews.com logoAlexza Pharmaceuticals (NASDAQ:ALXA) versus Endo International PLC (ENDP) Head-To-Head Comparison
www.americanbankingnews.com - July 19 at 8:42 PM
americanbankingnews.com logoAlexza Pharmaceuticals (NASDAQ:ALXA) versus Endo International PLC (ENDP) Head to Head Review
www.americanbankingnews.com - July 14 at 10:54 AM
americanbankingnews.com logoHead-To-Head Review: Alexza Pharmaceuticals (ALXA) versus Endo International PLC (ENDP)
www.americanbankingnews.com - July 2 at 7:54 AM
streetinsider.com logoGrupo Ferrer to Acquire Alexza Pharma (ALXA) for 90c/Share
www.streetinsider.com - June 22 at 3:27 PM
biz.yahoo.com logoALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisti
biz.yahoo.com - June 21 at 8:55 AM
biz.yahoo.com logoALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
biz.yahoo.com - June 16 at 4:10 PM
biz.yahoo.com logoALEXZA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 13 at 4:04 PM
biz.yahoo.com logoQ1 2016 Alexza Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - May 11 at 7:07 AM
biz.yahoo.com logoALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
biz.yahoo.com - May 10 at 6:15 AM
benzinga.com logoWorst Performing Industries For April 26, 2016 - Benzinga
www.benzinga.com - April 26 at 12:10 PM
biz.yahoo.com logoQ4 2015 Alexza Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 28 at 7:07 AM
biz.yahoo.com logoALEXZA PHARMACEUTICALS INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements an
biz.yahoo.com - March 24 at 4:14 PM
benzinga.com logoAlexza Pharmaceuticals Confirms Grupo Ferrer Non-binding LoI - Benzinga
www.benzinga.com - February 28 at 2:01 PM
thestreet.com logoAlexza Pharmaceuticals Confirms Grupo Ferrer Non-binding Letter Of Intent
www.thestreet.com - February 26 at 8:55 PM
streetinsider.com logoAlexza Pharma (ALXA) Reacquires ADASUVE Rights from Teva - StreetInsider.com
www.streetinsider.com - February 24 at 2:40 PM
biz.yahoo.com logoALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi
biz.yahoo.com - February 24 at 9:09 AM

Social

Chart

Alexza Pharmaceuticals (ALXA) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.